Eiger Cleared To Liquidate, Repay Creditors Under Ch. 11 Plan

By Alex Wittenberg · September 5, 2024, 6:43 PM EDT

Drug developer Eiger Biopharmaceuticals will wind down its business and distribute proceeds from sales of its rare-disease treatments to creditors and shareholders under a Chapter 11 plan approved by a Texas...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login